Shares of Biogen Inc. BIIB slipped 5.90% to $113.38 Thursday, on what proved to be an all-around rough trading session for ...

Guggenheim lowered the firm’s price target on Biogen (BIIB) to $165 from $168 and keeps a Buy rating on the shares. The firm, in its preview of ...

Shares of Biogen Inc. BIIB slipped 4.31% to $114.05 Tuesday, on what proved to be an all-around poor trading session for the ...

Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $152 from $157 and keeps an Equal Weight rating on the shares. The firm ...

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080 ...

But that doesn't mean long term investors can avoid big losses. For example the Biogen Inc. (NASDAQ:BIIB) share price dropped 56% over five years. That's an unpleasant experience for long term ...

The FDA has granted Fast Track designation to Biogen’s BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau for the treatment of Alzheimer disease (AD). In a press release ...

Happy to be moderating my annual panel where Priya has to listen to me pepper her with questions for 40 minutes or so with Priya Singhal, Head of Development at Biogen. Thank you, Priya for ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Biogen exits biosimilar JV with Samsung, raising $2.3bn News The South Korean firm just agreed to buy Biogen out of their biosimilar joint venture – Samsung Bioepis – for $2.3 billion.

Biogen, Inc. is a biopharmaceutical company ... and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...